05/24/03 - Montefiore
Franklin Charles Lowe, MD MPH
171 West 71 Street, Apt 4E
New York, NY 10023
Contact Information: FCLOWEMD@
(c) 917-865-6035
(o) 718-920-4531
Academic Training: Princeton University, B.A. 1975
Columbia University, M.D. 1979
Columbia University, M.P.H. 1979
Licenses: National Boards #211443 1980
Maryland #D26397 1981
Pennsylvania #MD032818-E 1984
New York #161-819 1985
Massachusetts #150229 1996-2112
Traineeship: Internship in Surgery Johns Hopkins 1979-1980
Residency in Surgery, Johns Hopkins 1980-1981
Residency in Urology, Johns Hopkins 1981-1982
Research Fellow in Urology, John Hopkins 1982-1983
Residency in Urology, Johns Hopkins 1983-1984
Board Qualifications: American Board of Urology #9115 1987
American Board of Urology Recertification 1995,2006,2015
Professional American Public Health Association 1976-1982
Organizations: American Medical Association 1978-2000
NY Section, American Urological Association 1986-present
1992-2001 Bylaws Committee
1993-2001 Chairman
1992-1994 Rep. AUA Audiovisual Com.
1993-2001 Rep. AUA Bylaws Committee
1998, 2003 Scientific Program Co-Chairman
2006-2009 Executive Board
American Urological Association 1987 – present
1993-2001 Bylaws Committee
1996-2003 BPH Guidelines Panel
1998-2009 Alternative Medicine Committee
2001-2009 Chairman
2001-present Annual Meeting Program Committee
2001-present Communications Comm., Expert Panel
St. Luke’s/Roosevelt Hospital
Physicians’ Organization 1986-1993
1987. Vice President
1987-1990 President
1990-1993 Secretary`
American Cancer Society 1986-1998
1993. Lecturer
1995. Professional Education
Grants Committee
American College of Surgeons 1988-2005
American Geriatrics Society 1988-1991
New York Academy of Medicine 1990-present
2001. Executive Board:
Section Urology
2000. Secretary
2001. President
New York State Urological Association 1993-present
American Association of Clinical Urologists 1993-present
Societe International D-Urologie 1994-present
AUA Foundation 2010-present
2010-2012 Education Council
Academic
Appointments: Instructor in Urology, John Hopkins 1985
Assistant Prof. of Clinic Urology, Columbia 1985-1994
Adjunct Asst. Prof. of Urology, Cornell 1987-2007
Associate Clinical Prof. of Urology, Columbia 1994-1997
Associate Prof. of Clinical Urology, Columbia 1997-2003
Professor of Clinical Urology, Columbia 2003-2014
Professor of Urology, Mount Sinai 2014-2015
Hospital
Appointments: Assistant Chief of Service Urology, John Hopkins 1985
Jr. Assistant Attending, St. Luke’s-Roosevelt 1985-1987
Associate Attending, St. Luke’s-Roosevelt 1987-1994
Senior Attending, St. Luke’s-Roosevelt 1995-2015
Assistant Attending, New York Hospital
Cornell Medical Center 1987-2013
Associate Attending, Columbia Presbyterian 1998-2013
Attending, Montefiore Medical Center 2015-present
Honors: Second Prize – Laboratory Research
Mid-Atlantic American Urological Association 1983
First Prize – Clinical Research
Mid-Atlantic, American Urological Association 1984
Best paper on Prostatic Disease, NY AUA 1992
Prostate Health Council-American Foundation
For Urologic Disease.
Castle and Connolly
Best Doctors in NY Metro Area 1997-present
Best Doctors in America 1998-present
America’s Top Doctors for Cancer 2000-present
New York Magazine 1998-2014
Best Doctors in New York
Pfizer Scholars in Urology 1998
Camp Winadu Humanitarian Award 1998
Teacher of the Year 2001
Columbia P & S, Urology
Marquis’ Who’s Who in America 2005
New York Times—Super Doctors 2008-present
SLD’s Guide to America’s Top Urologists 2009-present
America’s Choice - Most Compassionate Doctor 2008- present
Newsweek Magazine- Best Doctors for Cancer 2015
Grants: Abbott Laboratories 1989 -1990
Principal Clinical Investigator $66,000
Terazosin for BPH
Abbott Laboratories 1990 -1994
Principal Clinical Investigator $120,000
Long-term Therapy with Terazosin
Abbott Laboratories 199 2-1994
Principal Clinical Investigator $ 50,000
Terazosin vs. Placebo
Miles Pharmaceutical 1993 -1994
Principal Clinical Investigator $ 30,000
Low Dose Cipro for UTI
Abbott Laboratories 1994 -1998
Principal Clinical Investigator $ 30,000
Long-term Therapy with Terazosin
Merck 1988 -1992
Co-Investigator
Finasteride for BPH
Abbott Laboratories 1992 -1994
Co-Investigator
Terazosin vs. Placebo
Matrix Pharmaceutical 1993 -1994
Co-Investigator
5-FU Implant for Prostate Cancer
lCl-Zeneca 1992 -present
Co-Investigator
Combined Androgen Deprivation for Prostate Cancer
Vivus 1994 -1996
Co-Investigator
Intra-urethral Aprostadil for Impotence
ICl-Zeneca 1996-present
Co-Investigator
Adjunct Casodex Following Radical Prostatectomy
Gallaxo-Wellcome $20,000 1997-1998
Investigator
5 alpha reductase inhibitor for BPH
Merck $25,000 1999-2001
Investigator
Proscar for Hematuria
Novogen $20,000 1999-2000
Investigator
Trinovan (lsoflavone) or BPH
NIH-NIDDK 2002-2005
Co-Investigator
Phytotherapy for BPH
Departmental: Chief of Urology Clinics, St. Luke’s/Roosevelt 1985-2015
Director of Resident Education, SL/R 1986-2015
Associate Director, St. Luke’s 1989-2015
Hospital
Committees: Transfusion 1986-1999
Medical Options Planning 1986-1988
Future of St. Luke’s 1989-1994
St. Luke’s-Roosevelt PPO Planning 1990-1991
Medicaid Managed Care Planning 1992-1993
Managed Care 1993-1994
Physician/Hospital Task Force 1993-1994
Associate Director 1995-1997
Clinical Practice 2003-2007
Professional
Activities: Editorial
Journal of Urology, Reviewer 1988-present
Archives of Dermatology, Reviewer 1990
Urology, Reviewer 1993-present
Editorial Board 1998-2008
Associate Editor, Infections 1999-2008
Medical Letter, Editorial Consultant 1994
Pharmaco Economics, Reviewer 1996
AIDS, Reviewer 1996
AMA Drug Evaluations, Editorial Consultant 1994, 1997
Prostate Health. Com. Editorial Board 1997-2001
Pharmacopeia, Reviewer 1997-1998
Gender and Health, Editorial Board 1998-1999
Consumer Reports on Health, Reviewer 1998-present
Urology Research and Treatment, Editorial Board 1999-present
The 5 Minute Urology Consult, Section Editor 2000, 2010, 2014
Prostate Cancer and Prostatic Diseases
Consulting Editor 2000-2015
Office of Dietary Supplements, NIH
Botanical Fact Sheet 2002
Brazilian Journal of Urology
Consulting Editor, BPH 2005-present
Clinical Therapeutics
Editorial Consultant 2004-present
Consultant
Kellogg Grant to Johns Hopkins,
Advisory Board 1982-1985
PruCare of New York
Credentials Committee 1987 - 1992
Schering-Plough Pharmaceuticals,
Consultant, Sales Training 1990 – 1995 Chubb Health,
Physician Advisory Panel 1994 – 1998
4th International Consultation on BPH
Committee on Other Medical Therapies 1997
5th International Consultation on BPH
Co-Chairman, Committee on Other
Medical Therapies 2000
NIH Saw Palmetto Study
Data & Safety Monitoring Board 2000 – 2005
Columbia University Halth Service, Ask Alice
Health Information Service 1996 – 2002
Empire BC, Provider Appeals 2001 – 2002
3rd International Consultation on PCa
Committee on Supplemental Hormonal Treatment 2002
FDA – Special Drug Consultant 2002 – 2010
National Kidney Foundation –NY Section 2005 --2010
Medical Advisory Board
NIDDK Prostate Basic and Clinical Science Strategic Planning 2007
Committee
NY State-DOH Office Professional Medical Conduct 2008 - present
Medical Expert
Other Activities:
Princeton University
Schools Committee 1975 – 2006
Interviewer 1975 – 2005
Co-Chairman, Bronx 2003 – 2006
Annual Giving, Solicitor 1995 , 1998
P & S Alumni Association 1997 – 2002
Executive Council
Manhattan Soccer
Head Coach 1985-86 Travel Team 1995 – 2003
Head Coach 1988-89 Travel Team 1997 – 2001
Board of Directors 2000 – 2003
Second Vice President 2001 – 2002
Horace Mann School
Development Office 1989 – present
Class Agent 1995 – present
Annual Fund ’99, Chairman 1998 – 1999
Annual Fund 2000, Co-Chairman 1999 – 2000
Annual Fund 2001, Co-Chairman 2000 – 2001
Annual Fund 2002, Co-Chairman 2001 – 2002
Annual Fund 2003, Co-Chairman 2002 – 2003
Annual Fund 2004, Co-Chairman 2003 -- 2004
Capital Campaign, Alumni Chair 2002 – 2005
Annual Fund 2005, Co-Chairman 2004 –2005
Annual Fund 2006, Alumni Chair 2005-2006
The Dorilton Co-op Board of Directors 1998 – present
Congregation Rodeph Sholom 2002 – 2006
Board of Trustees
United States Soccer Federation 2003-2011
Certified Referee
Publications:
Peer Reviewed
1. Lowe,F.C. and Jeffs, R.D.: Wound Dehiscence in Bladder Exstrophy:
An Examination of the Etiologies and Factors for initial Failure and Subsequent Success.
J. Urol. 130:312-318, 1983.
2. Lowe,F.C: Squamous Cell Carcinoma of the Scrotum: A Review. J. Urol. 130:423-
427, 1983.
3. Lowe,F.C. and Jeffs, R.D.: lleal Trigonal Conduits: 10 Year Follow-up.
Urol. 130:874-877, 1983.
4. Lowe,F.C and Isaacs, J.T.: Biochemical Methods for Predicting Metastatic Ability
Of Prostatic Cancer Utilizing the Dunning R-3327 Rat Prostatic Adenocarcinoma System
as a Model. Cancer Research 44:744-752, 1984.
5. Lowe,F.C and Marshall, F.F.: Ureteropelvic Junction Obstruction in Adults.
Urology 23:331-336, 1984.
6. Brendler, C.B., Albertson, P.C. Goldman, S.M., Hill, G.S., Lowe, F.C. and Millan, J.D.:
Acquired Renal Cystic Disease in the End-Stage Kidney. J. Urol. 132:548-552, 1984.
7. Lowe,F.C and Brendler, C.B.: Penile Gangrene: A Complication of Secondary
Hyperparathyroidism from Chronic Renal Failure. J. Urol. 132:189-191, 1984.
8. Lowe,F.C.: Squamous Cell Carcinoma of the Scrotum. Urology 25:63-65, 1985.
9. Lowe,F.C and Mc Cullough, A.R.: Cutaneous Horns of the Penis: An approach
To Management. J. Amer. Acad. Dermatol. 12:369-373, 1985.
10. Lowe,F.C., Hill G., Jeffs, R.D. and Brendler, C.B.: Urethral Prolapse in Children:
Insights into Etiology and Management. J. Urol, 135:100-103, 1986.
11. Lowe,F.C., Auster, M., Geck, T. Chang, R. and Marshall,
F.F.: Monitoring Radiation Exposure to Medical Personnel During Percutaneous
Nephrolithotomy. Urology 28:221-226, 1986.
12. Gearhart, J.P. and Lowe, F.C.: Genitalia Injuries from Breakdancing in Children and
Adolescents. Pediatrics 77:92-924, 1986.
13. Somers, W.J. and Lowe,F.C.: Localized Gangrene of the Scrotum and Penis: A
Complication of Heroin Injection into the Femoral Vessels. J. Urol. 136:111-113,
1986.
14. Lowe,F.C. and Walther, J.M.: Case Profile: Emphysematous Pyelonephritis.
Urology 28:532-533, 1986.
15. Walther, J.M., Romas, N.A. and Lowe, F.C.: Barium Granuloma: An Unusual Cause
of Unilateral Ureteral Obstruction. J. Urol. 138:614-616, 1987.
16. Lowe,F.C. and Somers, W.J.: The Use of Ketoconazole in the Emergency
Management of Disseminated Intravascular Coagulation Due to Metastatic Prostate
Cancer. J. Urol. 137:1000-1003, 1987.
17. Walsh, P.C., Epstein, J.l. and Lowe, F.C.: Potency Following Radical Retropubic
Prostatectomy with Wide Unilateral Excision of the Neurovascular Bundle. J. Urol.
138: 823-827, 1987.
18. Oesterling, J.E., Goldman, S.M. and Lowe, F.C.: Intravesical Herniation of Small
Bowel Following Bladder Perforation. J. Urol. 138: 1236-1238, 1987.
19. Somers, W.J., TerPenning, BG., Lowe, F.C. and Romas, N.A.: Renal Parenchymal
Neurilemmoma: A Rare and Unusual Kidney Tumor. J. Urol. 139: 109-110, 1998.
20. Bamberger, M.H., and Lowe, F.C.: Ketoconazole in Initial Management and
Treatment of Metastatic Prostate Cancer to the Spine. Urology 32:301-303, 1988.
21. Lowe, F.C. , Fishman, E.K. and Oesterling, J.E.: Use of Computerized Tomography in
Diagnosis of Bladder Rupture. Urology 33:341-343, 1989.
22. Lowe, F.C., Lattimer, D.G. and Metroka, C.E.: Kaposi’s Sarcoma of the Penis in
Patients with Acquired Immune Deficiency Syndrome. J. Urol. 142:1475-1477, 1989.
23. Lowe, F.C., Goldman, S.M. and Oesterling, J.E.: Computerized Tomography in the
Evaluation of Transitional Cell Carcinoma in Bladder Diverticula.
Urology 33:390-395, 1989.
24. Lowe, F.C., and Bamberger, M.H.: The Indications for the Use of Ketoconazole in
the Management of Metastatic Prostate Cancer. Urology 36:541-545, 1990
25. Coleburn, N., Scholes, J. and Lowe, F.C.: Renal Failure in Patients with AIDS Related
Complex. Urology 37:523-527, 1991.
26. Sigalow, D.A., Waldbaum, R.S. and Lowe, F.C.: The Influence of Modern Radiographic
Imaging Techniques in Identifying Asymptomatic Renal Cell Carcinomas. New York
State Journal of Medicine 91:200-202, 1991.
27. Lepor, H., Auerback, S., Puras-Baez A., Narayan, P., Soloway, M. .Lowe, F.C., Moon, T.,
Leifer, G. and Madsen, P.: A Randomized, Placebo-Controlled Multicenter Study of
the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia
J. Urol. 148:1467-1474, 1992.
28. Kwan, D. and.Lowe, F.C.: Congenital Bladder Diverticulum: An Unusual Presentation
With Abdominal Mass, Urinary Retention and Renal Failure in a Young Adult.
Urologic Radiology 14:194-196, 1992.
29. Oesterling, J.E., Martin, S.M., Bergstralh, E.J. and .Lowe, F.C.: The Use of Prostate-
Specific Antigen in Staging Patients with Newly Diagnosed Prostate Cancer. J.A.M.A.
269:57-60, 1993.
30. .Lowe, F.C.: and Stark, E.: The Use of Alpha Blockers in the Management of Benign
Prostatic Hyperplasia. New York State Journal of Medicine 93:169-173, 1993.
31. Lowe, F.C. and Jarow, J.P.: Placebo Controlled Study of Oral Terbutaline and
Pseudoephedrine in the Management of Prostaglandin El induced Prolonged Erection.
Urology 42:51-54, 1993.
32. Trauzzi, S.J., Kay, C.J. Kaufman, D.G. and Lowe, F.C.: The Management
of Prostatic Abscess in Patients with Acquired Immunodeficiency Syndrome.
Urology 43:629-633, 1994.
33. Lowe, F.C.: Safety Assessment of Terazosin in the Treatment of Patients with
Symptomatic Benign Prostatic Hyperplasia: A Combined Analysis. Urology 44:46-
51 1994.
34. Kwan, D. and Lowe, F.C.: Genitourinary Manifestations of AIDS.
Urology 45:13-27, 1995.
35. Klein, L.T. and Lowe, F.C.: Penile Gangrene: Associated with Extensive
Kaposi’s Sarcoma in AIDS Patients. Urology 46:425-428, 1995.
36. Lowe, F.C.: McDaniel, R.L., Chmiel, J.J. and Hillman A.L.: Economic
Modeling to Assess the Costs of Treatment with Finasteride, Terazosin and
TURP for Men with Moderate to Severe Symptoms of BPH.
Urology 46:477-483, 1995.
37. Weiner, D.M. and Lowe, F.C.: Surgical Management of Penile Gangrene
in Diabetics with End-Stage Atherosclerosis. J. Urology 155:926-929, 1996.
38. Weiner, D.M. and Lowe, F.C.: Epididymo-Cutaneous Fistula in an AIDS
Patient with Marfan’s Syndrome. Urology 47:766-768, 1996.
39. Lowe, F.C.. and Ku, J.C.: Phytotherapy in the Treatment of BPH: A Critical
Reappraisal. Urology, 48:12-20, 1996.
40. Staiman, V.R., O’toole, K.C., Rubin, M.A. and Lowe, F.C.:. Giant Malignant Fibrous
Histiocytoma of the Testis/Spermatic Cord: Psychological and Possible Etiologic
Complication of Unethical Nazi Medical Experimentation. Urology 48:939-943, 1996.
41. McKierman, J. and Lowe, F.C.:. Update on Safety Terazosin in the Treatment of BPH.
Southern Medical Journal 90:509-513, 1997.
42. Weiner, D.M. McDaniel, R.L. and Lowe, F.C.:. Urological Manpower Issues for the
Twenty First Century: Assessing the Impact of Changing Population Demographics.
Urology 49:335-342, 1997.
43. Jarow, J.P. and Lowe, F.C.:. Penile Trauma: An Etiologic Factor in Peyronie’s Disease
and Erectile Dysfunction, J. Urol. 58” 1388-1390, 1997.
44. Lowe, F.C.:. The Concomitant Usage of Tamsulosin with Other Antihypertensives:
The Lack of Clinically Significant Interactions, Clinical Ther. 19: 30-42, 1997.
45. Staiman, V.R. and Lowe, F.C.:. Tamoxifen for Flutamide – Induced Gynecomastia.
Urology 50: 929-933, 1997.
46. Lowe, F.C.and Fagelman, E.: Phytotherapy in the Treatment of Benign Prostatic.
Hyperplasia. Current Opinion in Urology 8:27-29, 1998.
47. Weiner, D.M. and Lowe, F.C.: Psychotropic Drug Induced Priapism: Etiology and
Management. CNS Drugs 9: 371-379, 1998.
48. Klein, L.T. Frager, D. Subramanian, A. and Lowe, F.C.: Indications for the Use of
Magnetic Resonance Urography. Urology 92: 602-608, 1998.
49. Lowe, F.C.: Dreikorn, K., Borkowski, A., Braeckman, J. Denis, L., Ferrari, P., Gerber, G.,
Levin, R., Perrin, P., and Senge, T.: A Review of the Recent Placebo-Controlled
Trials Utilizing Phytotherapeutic Agents For The Treatment of BPH. Prostate 37:
187-193, 1998.
50. Lowe, F.C. and Fagelman E.: Phytotherapy in the Treatment of BPH: An Update.
Urology 53: 671-678, 1999.
51. Lowe, F.C., Olson P.J., Padley R.J.: The Effects of Terazosin Therapy on Blood
Pressure in Men with Benign Prostatic Hyperplasia Concurrently Treated With Other.
Antihypertensive Medications. Urology 54:81-85, 1999.
52. Albertsen P.C., Pellissier J.M., Lowe, F.C., Girman, C.J. and Roehrborn, C.G.:
Economic Analysis of Finasteride: A Model-Based Approach Utilizing PLESS Data..
Clinical Ther 21:1006-1024, 1999.
53. Lowe, F.C., and Fagelman, E.: Phytotherapy and Complementary Medications in
The Treatment of BPH and LUTS. Contemp. Urol. 14: 72-77, 1999.
54. Lowe, F.C.: The Role of Alpha-Adrenergic Anatagonists in The Treatment of BPH.
Prostate Cancer and Prostate Disease 2: 110-119, 1999.
55. Boyle, P., Robertson, C., Lowe, F.C.: and Roehrborn, C.: Meta-Analysis of Clinical Trials
Of Permixon in The Treatment of Symptomatic Benign Prostate Hyperplasia. Urology 55:
533-539, 2000.
56. Lowe, F.C.: and Fagelman, E.: Phytotherapy for Chronic Prostatitis. Current Urology-
Reports 1: 164-166, 2000.
57. Narayan, P. and Lowe, F.C.: The Effects of Tamsulosin on Vital Signs in Two Multicenter,
Placebo-Controlled Studies. Cardiovascular Reviews and Reports 21: 494-499, 2000.
58. Lowe, F.C. and Fagelman, E.: Cranberry Juice and Urinary Tract Infections: What is the
Evidence? Urology, 57: 407-413, 2001..
59. Lowe, F.C.: Phythotherapy in the Management of Benign Prostatic Hyperplasia
Urology 58 (6A): 71-77, 2001.
60. Fagelman, E. and Lowe, F.C.: Phythotherapy in the Treatment of Benign Prostatic Hyperplasia
Current Opinion in Urology, 12: 15-18, 2002.
61. Lowe, F.C.: Goals for Benign Prostatic Hyperplasia Therapy.
Urology 59 (2A): 1-2, 2002.
62. Marks, L., DiPaola, R.S., Nelson, P., Chen S., Heber, D., Belledegrun, A.S., Lowe, F.C., Fan, J., Leaders, F.E., Pantuck, A.J., and Tyler, V.E.: PC SPES: Herbal Formulation for Prostate Cancer. Urology 60: 369-377, 2002.
63. Lam, J., Romas, N.A. and Lowe, F.C.: Long-term Treatment with Finasteride in Men
With Symptomatic Benign Prostatic Hyperplasia: 10 Year Follow-up. Urology 61: 354-
358, 2003.
64. Lowe, F.C., et al: Long-term 6 Year Experience with Finasteride in Patients with
Benign Prostatic Hyperplasia: Urology 61: 791-796, 2003.
65. Lowe,F.C., Gilbert, S.M. and Kahane, H.: Evidence of Increased Prostate Cancer Detection in Men
Aged 50 to 59: A Review of 324,684 Biopsies Performed Between 1995 and 2002. Urology 62: 1045-49, 2003.
66. Weiner, D.M. and Lowe,F.C.: Alfuzosin for the Management of Benign Prostatic Hyperplasia.
Expert Opinion in Pharmacotherapy 4: 2057-2063, 2003.
67. AUA Practice Guidelines Committee: AUA Guideline on Management of Benign Prostatic Hyperplasia(2003)
Chapter 1: Diagnosis and Treatment Recommendations. J. Urol: 170:530-547, 2003.
68. Lowe,FC: Patient Risk Profiles for Progression of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH). European Urology: Supplement 3: 7-11, 2004.
69. Fagelman, E. and Lowe,F.C.: Permixon: An Update. Current Prostate Reports 2:133-136, 2004.
70. Boyle,P., Robertson, C., Lowe, F.C., Roehrborn, C.: Updated Meta-analysis of Clinical Trials of Serenoa Repens Extract in the Treatment of Symptomatic Benign Prostatic Hyperplasia. BJU Int 93:751-757, 2004.
71. Lowe, F.C.: Role of the Newer Alpha-Adrenergic-Receptor Antagonists in the Treatment of Benign Prostatic Hyperplasia-Related Lower Urinary Tract Symptoms. Clinical Therapeutics: 26:1701-1713, 2004.
72. Levinson, A., Nagler, E.A., Lowe, F.C.: Approach to Management of Clinically Localized Prostate Cancer in HIV Positive Patients. Urology: 65: 91-94, 2005.
73. Lowe, F.C., Batista J., Berges, R., Chartier-Kastler, E., Conti, G., Desgrandchamps, F., Dreikorn, K., O’Leary, M., Perez, M.,Speakman, M., Trachtenberg, J., Tubaro, A., Meesen, B., Smets, L., Stovelaar, H.: Risk Factors for Disease Progression in Patients with Lower Urinary Tract Symptoms/Begnin Prostatic Hyperplasia (LUTS/BPH): A Systematic Analysis of Expert Opinion. Prostate Cancer & Prostate Diseases 8: 206-209, 2005.
74. Gilbert, S.M., Cavallo, C.B., Kahane, H., Lowe, F.C.: Evidence Suggesting a PSA Cut-Point of 2.5 nanograms
per milliliter for Prompting a Prostate Biopsy: A Review of 36,316 Patients. Urology 65: 549-553, 2005.
75. Santillo, V.M. and Lowe, F.C.: Prostate Cancer and the Gay Male. J. Gay & Lesbian Psychotherapy
9: 9-27, 2005.
76. Lowe, F.C.: Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Sexual Function. BJU Int.
95: (s4) 12-18, 2005.
77. Speakman, M., Batista, J., Berges, J., Chartier-Kastler, E., Conti, G., Desgrandchamps, F., Dreikorn, K.,
Lowe,F.C., O’Leary, M., Perez, M., Trachtenberg, J., Tubaro, A., Meesen, B., Smets, L., Stovelaar, H.:
Integrating Risk Profiles for Disease Progression in the Treatment Choice for Patients with Lower UrinaryTract
Symptoms/Benign Prostatic Hyperplasia: A Combined Analysis of External Evidence and Clinical Expertise.
Prostate Cancer & Prostate Diseases 8: 369-374, 2005.
78. Santillo, V.M. and Lowe,F.C.: Role of Vitamins, Minerals and Supplements in the Prevention and Management
of Prostate Cancer. Brazilian International J. Urol 32:3-14, 2006.
79. Santillo, V.M. and Lowe,F.C. : Treatment of Prostatitis in HIV Positive Patients. Current Urol Reports. 7:313-319, 2006.
80. Santillo, V.M. and Lowe, F.C.: The Management of Chronic Prostatitis in Men with HIV. Current Prostate Reports 4:93-99, 2006.
81. Santillo, V.M. and Lowe, F.C.: Cranberry Juice for the Prevention and Treatment of Urinary Tract Infections.
Drugs of Today 43: 47-54, 2007.
82. Sprenkle, P.C. and Lowe, F.C.: Benign Prostate Hyperplasia in the Older Male. Aging Health 3:177-189, 2007.
83. Lowe, F.C. and Patel, T.: Complementary and Alternative Medicine in Urology: What We Need to Know in 2008. BJU Int 97: 422-424, 2008.
84. Moyad, M.A. and Lowe,F.C.: Educating Patients About Lifestyle Medications for Prostate Health. Am. J. Med.
121: S34-S42, 2008.
85. Lowe, F.C.: The Role of Serenoa repens in the Clinical Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. European Urology Sup 8: 894-897, 2009.
86. Wosnitzer, M.S. and Lowe, F.C.: Management of Prostate Cancer in HIV-positive Patients. Nat. Rev. Urol.
7:348-357, 2010.
87. Weiss, J.P., Blavais, J.G., Bliwise, D.L., Dmochowski, R.R., DuBeau,C.E., Lowe, F.C., Petrou, S.P., and van Kerrebroeck, P.E.V., Rosen, R.C., and Wein, A.J.: The Evaluation and Treatment of Nocturia: A Consensus Statement. BJU Int 108:6-21, 2011.
88. Suh, L.K. and Lowe,F.C.: Alternative Therapies for the Treatment of Chronic Prostatitis.
Current Prostate Reports 12:284-287, 2011.
89. Cubillos, J., Palmer, J.S., Freedman, S.C., Fregel, J., Lowe, F.C., and Palmer, L.: Familial Testicular Torsion.
J. Urol 185: (6 suppl) 2469-72, 2011.
90. Rhoerborn, C., Lowe,F.C., Gittelman, M., Verbeek, A.E, Wruck, J.: Feasibility of An Alternative Option For Management of Male Lower Urinary Tract Symptoms. J Urol 195: in press, 2016.
Invited Articles:
1. Oesterling, J.E. and Lowe,F.C.: Squamous Cell Carcinoma of the Scrotum.
AUA Update Series: 1X, 178-184, 1990.
2. Lowe,F.C. and Barnswell C.: Urinary Tract Infestions in Women.
The Female Patient 19: 19-26, 1994.
3. Ku, J.C. and Lowe,F.C..: Current Approach to Interstitial Cystitis.
The Female Patient 20: 27-34, 1995.
4. Kay, C.J., Trauzzi, S.J. and Lowe,F.C..: Prostatic Abscess in Patients.
with Acquired Immunodeficiency Syndrome: Imaging and Management.
Infections in Urology 8:86-90, 1995.
5. Staiman, V.R. and Lowe,F.C..: The Spectrum of Prostatic Diseases in
HIV Patients: Prostatic Abscess – An Emerging Problem. The AIDS Reader
5: 165-171, 1995.
6. Kwan, D. and Lowe,F.C..: Acquired Immunodeficiency Syndrome in Urology:
Part 1: AIDS and the Urologist. AUA Update Series XIV:297-304, 1995.
7. Kwan, D. and Lowe,F.C..: Acquired Immunodeficiency Syndrome in Urology:
Part 1l: Genitourinary Manifestations of AIDS. . AUA Update Series XIV:-305-312, 1995.
8. Kay, C.J., Trauzzi, S.J. and Lowe,F.C..: Imaging and Management of Prostatic Abscess
Associated With the HIV syndrome. Infections in Medicine 12:535-539, 1995.
9. Staiman, V.R. and Lowe,F.C..: Prostatic Disease in HIV-Infected Patients.
Infections in Urology 9:42-47, 1996.
10. Staiman, V.R. Kwan D..and Lowe,F.C..: Genitourinary Manifestations of AIDS.
Infections in Urology 9:73-77,92, 1996.
11. Klein, L.T. Lowe,F.C..: HIV in Women. Update on Transmission.
The Female Patient 21:13-21, 1996.
12. Staiman, V.R., Kwan, D.J. and Lowe,F.C.: HIVand the Genitourinary Tract.
Infections in Medicine 13:598-608, 1996.
13. Lowe,F.C..: Saw Palmetto Berry in the Treatment of BPH, Clin. Res. Reg. Affairs.
14:53-66, 1997.
14. Staiman, V.R. and Lowe,F.C..: Prostatic Disease in HIV-Infected patients. Primary
Care Review: Update on Urology, 3: (1) 19-24, 1997.
15. Staiman, V.R. Kwan, D.J. and Lowe,F.C..: Genitourinary Manifestations of AIDS.
Care Review: Update on Urology, 3: (1) 9-15, 1997.
16. Weiner, D.M. and Lowe,F.C..: Gangrene of Penis. AUA Update Series: XVII, 42-49,
1998.
17. Lowe,F.C. and Fagelman E.: Using Complementary Medications to Treat BPH.
Patient Care :191-203,2000.
18. Fagelman, E., and Lowe, F.C.: Using Complementary Medications for BPH. Reviews
in Urology, 3:134-138, 2001.
19. Hyun, G., Staiman V.R. and Lowe, F.C: Urological Problems in Patients with Acquired
Immunodeficiency Syndrome. AUA Update Series: XXI, 313-320, 2002.
20. Johnson, C., Lowe, F.C., and Johnson, W.D.: Tuberculosis of the Genito-urinary System.
AUA Update Series: XXII: 301-308, 2003.
21. Staiman V.R. and Lowe, F.C.: Urologic Problems in Patients with Acquired Immunodeficiency Syndrome.
Scientific World J 4: (S1) 427-437, 2004.
22. Lowe,F.C.: Summary of Clinical Experiences With Tamsulosin for the Treatment of Benign
Prostatic Hyperplasia. Reviews in Urology 7: (S4), S13-S21, 2005.
23. Lowe,F.C. and Nagler, E.: Prostate Biopsy in the Diagnosis of Prostate Cancer: Current Trends and
Techniques. Drugs Today 41:179-191, 2005.
24. Santillo, V.M. and Lowe, F.C.,: Phytotherapy for BPH. AUA Update Series: XXV: in press, 2006.
25. Santillo, V.M. and Lowe, F.C. : Treatment of BPH in Men with Cardiovascular Disease.
Drugs and Aging 23:795-805, 2006.
26. Lowe, F.C.: Vitamins and Supplements: Concerns About Safety. AUA News 12:21, May, 2007.
27. Hansen, A.M., Santillo, V.M. and Lowe, F.C.: Phytotherapy for Benign Prostatic Hyperplasia.
Timely Top Med Urology. 8: E23, Oct, 2007.
28. Chughtai, B., Kavaler, E., Te, A., Kaplan, S.A. and Lowe, F.C. : Use of Herbal Supplements for Over Active
Bladder. Reviews in Urology 15:93-96, 2013.
29. Lowe,F.C. and Sunyaro,P.: Relationship Between the Metabolic Syndrome and Prostate Cancer.
AUA News 20(1)14, 2015.
Invited Chapters:
1. Lowe, F.C.: Surgery for Gangrene of the Male Genitalia. In Operative
Urology, Edited by F.F. Marshall, W.B. Saunders & Co.: Chapter 50 p 377-385, 1991.
2. Lowe, F.C. and Brendler, C.B.: Initial Evaluation of the Urological Patient. In
Campbell’s Urology, Sixth Edition, Edited by P.C. Walsh, W.B. Saunders & Co.:
1992.
3. Kwan, D. and Lowe, F.C.: Acquired Immunodeficiency Syndrome: A Venereal
Disease. Urol. Clinics N. Amer. 19:13-24, 1992.
4. Lowe, F.C.: Squamous Cell Carcinoma of the Scrotum. Urol. Clinics N. Amer.
1992.
5. Lowe, F.C.: and Lepor, H.: Alpha Blockers in the treatment of Benign Prostatic
Hypertrophy. In Management of Benign Prostate Hyperplasia. Edited by N.A. Romas
and E.D. Vaughan, Springer-Verlag: 173-183, 1993.
6. Lowe, F.C. and Trauzzi, S.J.: Prostatic Acid Phosphatase in 1993: It’s Limited
Clinical Utility. Urol. Clinics N. Amer. 10: 589-596, 1993.
7. Lowe, F.C.: Surgery for Gangrene of the Male Genitalia. In Operative Urology,
Second Edition, Edited by F.F. Marshall, W.B. Saunders & Co.: Chapter 79, 1996.
8. Lowe, F.C. and Klein, L.: Management of Scrotal Carcinoma. In Current
Management of Genitourinary Cancer Surgery, Edited by D. Crawford and S. Das, Lea
and Febinger: 545-549, 1996.
9. Klein, L.T. and Lowe, F.C.: The Effect of Digital Rectal Examination and Various
Lower Urinary Tract Procedures on Serum PSA Concentrations. Urol. Clinic
North Amer. 24: 293-298, 1997.
10. Lowe, F.C. and Standaert, B.: Health Economics of BPH. Benign Prostatic Hyperplasia—The Place of Alfusosin. Edited by Debruyne, FMJ et al. Adis: 103-118, 1998.
11. Staiman, V.R. and Lowe, F.C.: Urologic Problems in Patients with Acquired
Immunodeficiency Syndrome. Digital Urol. J. ., 1998.
12. Health Economics of BPH. Benign Prostatic Hyperplasia—The Place of Alfusosin. Edited by Debruyne, FMJ et al. Adis: 103-118, 1998.
13. Dreikorn, K., Borkowski, A., Braeckman, J., Denis, L., Ferrari, P., Gerber, G., Levin, R.,
Lowe, F.C., Perrin, P. Medical Therapies. In Proceedings of 4th.
International Consultation on Benign Prostatic Hyperplasia. Edited by Denis, L.,
Griffiths, K., Khoury, S. et al. Health Publication Ltd. 633-659, 1998.
14. Lowe, F.C., and Fagelman, E.: Phytotherapy in the Treatment of Prostatitis. In
Prostatitis Edited by J.C. Nickel, ISSIS Medical Media: 329-331, 1999.
15. Staiman, V.R. and Lowe, F.C..: Gynecomastia. In Five Minute Urology Consult,
Edited By L.G. Gomella, Lippincott, Williams and Wilkins, 58-59, 2000.
16. Kearney, M.C. and Lowe, F.C.: Squamous Cell Carcinoma of the Scrotum. In The Five
Minute Urology Consult, Edited by L.G. Comella, Lippincott, Williams and Wilkins.
494-495, 2000.
17. Taylor, J. and Lowe, F.C.: Alternative Therapies in Urology. In The Five Minute Urology
Consult, Edited by L.G. Gomella, Lippincott, Williams and Wilkins, 769-772, 2000.
18. Dreikom, K., Lowe, F.C., Borkowski, A., Buck, H.C., Braeckman, J., Denis, L., Ferrari, P
.,.: Habib, F., and Perrin, P., Other Medical Therapies. In Proceedings of 5th
International Consultation on Benign Prostatic Hyperplasia. Edited by Chatelin, C.,
Denis, L., Foo K.T. et. Al, Health Publications Ltd: 479-511, 2001.
19. Fagelman, E., and Lowe, F.C.: Herbal Medications in the treatment of BPH. Urol Clinic
North Amer. 29:31-48, 2002.
20. Lepor, H. and Lowe F.C.: Evaluation and Nonsurgical Management of Benign Prostatic Hyperplasia. In Campbell’s Urology, Eight Edition, Edited by P.C. Walsh, et al, W.B. Saunders & Co., 2002.
21. Johnson, W., Johnson, C. and Lowe, F.C.: Tuberculosis and Parasitic Diseases of the
Genitourinary System. In Campbell’s Urology, Eighth Edition, Edited by P.C. Walsh, et al, W.B.
Saunders & Co., 2002
22. Hyun, G. and Lowe, F.C.: AIDS and the Urologist. Urol Clinics of N. American. 30: 101-
109, 2003.
23. Fagelman, E., Mennite, B., and Lowe, F.C.: Complementary Medications in Urology. In Essential Urology edited by J.M. Potts, Humana Press: 225-234, 2004.
24. Fagelman, E. and Lowe, F.C.: Reviewers of clinical trials of saw palmetto berry, cranberry, pygeum, and
grass pollens. In The Handbook of Clinically Tested Herbal Remedies. Edited by M. Barrett, Haworth Herbal Press: 265-276, 773-786, 981-1010, 1043-1100, 2004.
25. Santillo, V.M. and Lowe, F.C.: Prostate Cancer and The Gay Male. In A Gay Man’s Guide to Prostate Cancer,
Edited by G. Perlman and J. Drescher, Haworth Medical Press: 9-27, 2005.
26. Lowe, F.C. and Moyad, M.: Alternative Urologic Therapies (Phytotherapies). In The Five
Minute Urology Consult, Edited by L.G. Comella, Lippincott, Williams and Wilkins: 725-729, 2010.
26. Wosnitzer, M.S. and Lowe, F.C.: Prostate Cancer Management in the HIV-Positive Patients in the Era of Highly-Active antiretroviral Therapy (HAART). In What Every Gay Man Needs to Know About Prostate Cancer.Edited by G. Pearlman. Magnus Books, 2013.
27. Santillo, V.M. and Lowe, F.C.: Quality-of-Life and Cancer Control after Prostate Cancer Treatment. In What Every Gay Man Needs to Know About Prostate Cancer.Edited by G. Pearlman. Magnus Books, 2013.
28. Wosnitzer, M.S., Ahn, J. and Lowe,F.C.: HIV and Prostate Cancer. Prostate Cancer: A Comptrehensive Perspective. Edited by Ashutosh Tewari. Springer, Chapter 10, 2013.
29. Tu, D and Lowe,F.C.: Nocturia: Treatment with alternative Therapies. In Nocturia. Edited by
J. Weiss and J. Blavais, Springer: 157-164, 2011.
30. Lowe, F.C.: A Straight Urologist Discusses Working with Gay Men Who Have Prostate Cancer. In What Every Gay Man Needs to Know About Prostate Cancer.Edited by G. Pearlman. Magnus Books, 2013.
31. Wenske, S and Lowe,F.C.: Complementary and Alternative Medicine. In The Five Minute Urology Consult,
Edited by L.G. Gomella, Wolters Kluwer, 2014.
Invited Miscellaneous Articles:
1. Lowe,F.C.: Book Review: Difficult Diagnosis in Urology by David McCullough.
Urol. 141:669, 1989.
2. Lowe,F.C.: Editorial Comment: Long-Term Follow-up Results After Expectant.
Management of Stage A1 Prostatic Cancer by Zhang, G., et al. J. Urol.
102-103, 1991.
3. Lowe,F.C.: Book Review: Cancer of the Prostate Edited by S. Das and
David Crawford. J. Urol. 150: 2040, 1993.
4. Lowe,F.C.: Safety and Efficacy of Terazosin in the Management of BPH.
AUA Today September, 1994.
5. Lowe,F.C.: Good News for Hypertensives with BPH. Modern Medicine
24, 1995.
6. Lowe,F.C.: Editorial: Diagnosis and Staging of Prostate Cancer.
Urol. 156: 114, 1996.
7. Lowe,F.C.: Editorial: Quality of Life After Partial Penectomy For Penile Carcinoma.
Urology 50: 596, 1997..
8. Lowe,F.C.: Editorial: Saw Palmetto Berry in Men with LUTS. Urology, 51: 1007, 1998.
9. Lowe,F.C.: What I Tell Patients About Phytotherapy for Lower Urinary Tract Symptoms.
AUA News, 5: (3) 12, 1998.
10. Lowe,F.C.: and Weber, M.L.: Defining the Link Between Benign Prostatic Hyperplasia
and Hypertension. Scientific Exchange, 1998.
11. Lowe,F.C.: Guidelines for the Evaluation and Management of BPH. Institute for Continuing Healthcare Education and Medicom of Princeton, 1998.
12. Lowe,F.C.: New Considerations in the Selection of Appropriate Alpha 1-Adrenergic
agonists in the Management of BPH. In New Concepts in Medical Management of
BPH, MPE Communications 4-8, 1998.
13. Narayan, P. (Moderator): Roundtable Discussion on BPH: Issues no the Use of Alpha
Urology Times 27: supplement #1, 1999.
14. Lowe, F.C.: Book Review. Testicular and Penile Cancer. J. Urol. 161: 736-736, 1999.
15. Lowe, F.C.: Chronic Prostatitis: An Update. In Diseases of the Prostate – A Postgraduate
Medicine Special Report 18-25, 1999.
16. Lowe, F.C.: Editorial: Natural Therapies: Questions, Uncertainties Abound. Urology Times.
(5): 2, 30, 2000.
17. Lowe, F.C.: Penile Enlargement: Think Hard Before Taking the Risk. Gay Health. Natural Therapies: Gayhealth. Com/templates. May, 2000.
18. Lowe, F.C.: Complementary Medications. In John Hopkins Medical Institutions Prostate.
Bulletin: 25-33, September 2000.
19. Lowe, F.C.: Editorial: Efficacy of Chemotherapy for Prostatic Tuberculosis – A Clinical and Histologic Follow-up Study. Urology 57: 877, 2001.
20. Lowe, F.C.: Editorial: Bacterial Interference for Preventing Urinary Tract Infections. Urology
58: 344, 2001.
21. Lowe, F.C.: Editorial: Acupuncture Ameliorates Symptoms in Men with Chronic Prostatitis/Chronic
Pelvic Pain Syndrome. Urology 61: 1159, 2003.
22. Lowe, F.C.: Benign Prostatic Hyperplasia and Hypertension. Urology Leader’s Forum, #1, 2004.
23. Lowe, F.C.: Editorial: Povidone Iodine and Dextrose Solution Combination Sclerotherapy in Chyluria.
Urology 64: 1110, 2004.
24. Lowe, F.C.: Editorial Comment: Are bone scans necessary in men with low prostate specific antigen levels
following localized therapy. J.Urol 176:73, 2006.
25. Lowe, F.C.: Editorial: Effects of One-Year Treatment with Isoflavone from Red Clover on Prostate,
Liver Function, Sexual Function and Quality of Life in Men with Elevated PSA Levels and Negative Prostate
Biopsy Findings. Urology 71: 190, 2008.
26. Lowe,F.C.: Editorial: Preliminary Results of Radiation Therapy for Prostate Cancer in HIV Positive Patients.
Urology 72: 1138, 2008.
27. Lowe,F.C.: Editorial: Contemporary Patients With Lower Urinary tract Symptoms Suggestive of Benign
Prostatic Hyperplasia Who Need Surgical Treatment Have Long-Term History of Treatment With Alpha 1 Blockers and Large Prostates Compared to Past Cases. Urology 74: 609, 2009.
28. Lowe,F.C. : Editorial: Silodosin in the treatment of BPH/LUTS. Urology 74: 1323, 2009.
Abstracts:
1. Oesterling, J.E., Bromberg, W.D. and Lowe F.C.: Localization of foreign body in the
penis using pre-operative xeroradiography and intra operative ultrasonography.
Mid-Atlantic Section of American Urological Association, September 28-31, 1986,
Southhampton, Bermunda.
2. Walsh, P.C. and Lowe, F.C.: Potency Following Radical Retropubic Prostatectomy
with Wide Unilateral Excision of the Neurovascular Bundle. Mid-Atlantic Section of
American Urological Association, September 28-31, 1986, Southampton, Bermunda.
3. Romas, N.A., Lowe, F.C. Clark L, MacKenzie, J.W. and Win, L: RNA
Catabolites As Cancer Markers in Urinary Tract Tumors. American Urological Potency Following Radical Association, June 3-7, 1988, Boston, MA.
4. Coleburn, N.H., Lowe, F.C. and Romas, N.A.: Renal Disease in patients with
AIDS and ARC. New York Section of American Urological Association,
September 24-31, 1988, Amsterdam, The Netherlands.
5. Nakhla, A.M., Romas, N.A., Lowe, F.C. and Rosner, W.: Estradiol Activates the Prostate
Androgen Receptor and PSA Secretion Through the Intemidiary of Sex Homone-,
Binding Globulin. 4th International Consultation on BPH, July 2-5, 1997, Paris, France.
6. Albert, P., Pellissier, J., Lowe, F.C., Giman, C. and Roehrborn, C.: Economic Implications
of Effects of Finasteride on The Rise of Acute Urinary Retention and Need for
Surgery. American Urological Association, May1-6, 1999, Dallas, Texas.
7. Boyle, P., Robertson, C., Lowe, F.C., Roehrborn, C.: Meta-Analysis of Permixon in
Treatment of Symptomatic Benign Prostatic Hyperplasia: An Update. American Urological
Association, April 28, 2003, Chicago, Illinois.
8. Levinson, A., Santillo, V.M., Hansen, A., Lowe, F.C.: Five Year Outcomes of Clinically Localized Prostate
Cancer in Patients with Human Immunodeficiency Virus. J Clin Oncology, 2008 ASCO Annual Meeting
Proceedings Part 1. Vol 26, #15s (May 20 supplement), 2008: 16095.
9. Roehrborn, C., Lowe, F.C., Gittelman M., Verbeek, A., Wruck, J.: . Management of Male Lower Urinary
Tract Symptoms: Ability to Correctly Identify and Consequences of Incorrect Consumer Decision.
Societe Urologe International, October 17, 2015, Sydney, Australia.
10. Gittelman, M., Roehrborn, C., Lowe, F.C.,Verbeek, A. and Wruck, J.: An Alternative Model for the Management of Lower Urinary Tract Symptoms Presumed to be Due to Benign Prostatic Hyperplasia. Societe Urologe International, October 16, 2015, Sydney, Australia.
11. Lowe, F.C , Gittelman, M., Roehrborn, C., Verbeel, A. and Wruck, J.: Microscopic Hematuria Screening in a Male Consumer Population with Lower Urinary Tract Symptoms. . Societe Urologe International, October 16, 2015, Sydney, Australia.
Scientific Presentations:
1. Wound Dehiscence in Exstrophy. American Academy of Pediatrics,
October 23-28, 1982, New York, NY.
2. Wound Dehiscence in Bladder Exstrophy: An Examination of the Etiologies
and Factors of Initial Failure and Subsequent Success. American Urological
Association, April 17-21, 1982, Las Vegas, Nevada.
3. A Study of Metastasis of Prostatic Cancer in the Dunning R-3327 Animal Model.
Mid-Atlantic Section of the American Urological Association, October 2-7, 1983,
Hot Springs, Virginia.
4. Illeal Trigonal Conduits: 10-Year Follow-up. Mid-Atlantic Section American
Urological Association, October 2-7, 1983, Hot Springs, Virginia.
5. Ureteropelvic Junction Obstruction in Adults. Mid-Atlantic Section American
Urological Association, October 2-7, 1983, Hot Springs, Virginia.
6. Ileal Trigonal Conduits: 10 Year Follow-Up. American Academy of Pediatrics,
October 28-31, 1981, San Francisco, California.
7. Urethral Prolapse: A Clinical and Anatomical Study. Mid-Atlantic Section of the
American Urological Association, November 1-4, 1984, White Sulphur Springs,
West Virginia.
8. Monitoring Radiation Exposure to Medical Personnel during Percutaneous
Nephrolithotomy. Mid-Atlantic Section of the American Urological Association
November 1-4, 1984, White Sulphur Springs, West Virginia.
9. Urethral Prolapse: Identification of the Anatomical Defects and Insights into
its Management. Society of University Urology Residents, May 8-11, 1985,
Pine Mountain, Georgia.
10. Monitoring Radiation Exposure to Medical Personnel during Percutaneous
Nephrolithotomy. American Urological Association, May 12-1, 1985, Atlanta,
Georgia.
11. Potency Following Radical Retropubic Prostatectomy with Wide Unilateral Ex-
cision of the Neurovascular Bundle. New York Section of the American
Urological Association, October 27-31, 1986, Laguna Nigel, California.
12. Indications for the Use of Ketoconazole in the Initial Management of Prostate
Cancer. American Urological Association, May 17-21, 1987, Anaheim, California.
13. The Epidemiology of Kaposi’s Sarcoma of the Penis in Patients with Acquired
Immune Deficiency Syndrome. American Urological Association, June 3-7, 1988,
Boston, Massachusetts.
14. Renal Failure in Patients with AIDS Related Complex. American Urological
Association, May 7-11, 1989, Dallas, Texas.
15. Terazosin: Efficacy and Safety in the Treatment of BPH. New York Section,
American Urological Association, October 19-24, 1992, Berlin, Germany.
16. The Role of Bone Scans in the Evaluation of Newly Diagnosed Prostate Cancer
in the PSA Era: A Critical Reappraisal. New York Section, American Urological
Association, October 19-24, 1992, Berlin, Germany.
17. The Economic Impact of Using PSA to Elimate the Staging Radionuclide Bone Scan
in Select Patients with Newly Diagnosed Prostate Cancer. American
Urological Association, May 15-20, 1993, San Antonio, Texas.
18. Oral Medical Therapy for the Treatment of Prostaglandin Induced Prolonged
Erections. American Urological Association, May 15-20, 1993, San Antonio,
Texas.
19. Long Term Safety and Efficacy of Terazosin in the Treatment of BPH: An
Interim Analysis. New York Section, American Urological Association,
Oct. 10-16, 1993, Venice, Italy.
20. Safety Assessment of Terazosin in the Treatment of BPH. American Geriatrics
Society, May 9-12, 1994, Los Angeles, California.
21. Safety Assessment of Terazosin in the Treatment of Patients with Symptomatic
BPH. A Combined Analysis. Mid-Atlantic Section, American Urological Association.
September 24, 1994, Philadelphia, Pennsylvania.
22. Safety Assessment of Terazosin in BPH. Northeastern Section, American Uro-
logical Association, September 25-29, 1994, Bolton’s Landing, New York.
23. Blood Pressure effects of Men with Prostatism Concurrently Treated with Anti-
hypertensives and Terazosin. American Urological Association, April 24, 1995,
Las Vegas, Nevada
24. Economic Modeling to Assess Cost-Effectiveness of BPH Therapies. International
Society of Technology Assessment in Health Care, June 6, 1995, Stockholm, Sweden.
25. Indications for the Use of Magnetic Resonance Urography. American Urological Association,
May 6, 1996, Orlando, Florida.
26. Creation of a Markov Model to Assess the Cost-Effectiveness of Various treatments
for BPH. American Urological Association, May 7, 1996, Orlando, Florida.
27. Follow-up of High Grade PIN: Clinical Implications. American Urological Association,
May 7, 1996, Orlando, Florida.
28. Clinical Implication of High Grade PIN, New York Section, American Urological
Association, October 6-11, 1996, Paris, France.
29. Concomitant Use of Tamsulosin With Antihypertensives: The Lack of Clinically
Significant Interactions. American Urological Association, April 12, 1997,
New Orleans, LA.
30. The Treatment of Flutamide and Finasteride Induced of Painful Gynecomastia with
Tamoxifen. American Urological Association, April 14, 1997, New Orleans, LA.
31. Concomitant Use of Tamsulosin. 4th International Consultation on BPH, July 2-5
1997, Paris, France.
32. Terazosin Treatment of Concomitant Symptomatic Benign Prostatic Hyperplasia and
Isolated Systolic Hypertension. Societe International Urologie, Sept. 11, 1997, Montreal
Canada..
33. Phytotherapy for BPH, New York Section, American Urological Association,
Lisbon, Portugal, October 22, 1997.
34. New Medical Therapies for BPH New York Section, American Urological Association,
Lisbon, Portugal, October 22, 1997.
35. 4 Month Safety and Efficacy of Terazosin in the Treatment of Symptomatic BPH.
European Association Urology, Iona, Spain, March 21-24, 1998.
36. Meta analysis of the treatment of BPH with Permixon. American Urological
Association, June 1, 1998, San Diego, CA, June 1, 1998.
37. The Effects of Tamsulosin Upon Serum PSa and Lipid Levels. New York Section,
American Urological Association, Oct. 14, 1998, Prague, Czech Republic.
38. Efficacy and Tolerability of Tamsulosin in Patients less than 65 Years and
greater than 65 years with benign prostatic hyperplasia, American Urological
Association, May 4, 1999, Dallas, Texas.
39. Prospective Randomized, Multicenter Trial to Evaluate the Rapidity of Onset and Side-
Effect Profile of Tamsulosin versus Terazosin in Men with Benign Prostatic Hyperplasia.
European Urological Association, February 25, 2002, Birmingham, England.
40. Epidemiological Evidence of Increased Prostate Cancer Detection in Particularly Younger
Men Aged 50-59: A Review of 311,655 Biopsies Performed From 1995-2001. American
Urological Association, May 26, 2002, Orlando, FL.
41. Prospective Clinical Trial Comparison of Tamsulosin and Terazosin. American Urological
Association, May 28, 2002, Orlando, FL.
42. Finasteride Therapy for BPH: 10 Year Follow-UP. American Urological Association,
May 29, 2002, Orlando, FL. Association, May 28, 2002, Orlando, FL.
43. Analysis of 233,989 Prostate Biopsies From 1997 to 2002 Confirms the Trend of
Decreasing Age of Patients Undergoing Prostate Biopsy But Does Not Demonstrate Any
Alteration in the Overall Detection Rate of Prostate Cancer. American Urological
Association, April 27, 2003, Chicago, IL.
44. Epidemiological Evidence Suggesting a PSA Cut-Point of 2.5 NG/ML For Initiating A
Prostate Biopsy: A Review of 36,316 Patients With Biopsy and PSA Data. American
Urological Association, April 29, 2003, Chicago, IL.
45. Changing Patterns of Prostate Biopsy Techniques From 1997 to 2002: A Review of 233, 989 Biopsies. American Urological Association, April 30, 2003, Chicago, IL.
46. Diet, Supplements and Drugs in the Prevention of Prostate Cancer. New York Section, American Urological
Association, October 12, 2003, Athens, Greece.
47. Long-term Management of BPH with Finasteride Monotherapy: 10 Year Follow-Up. New York Section,
American Urological Association, October 13, 2003, Athens, Greece.
48. Economic Comparison of Uro-selective Alpha-Blockers in the Management of BPH. New York Section,
American Urological Association, October 15,2003, Crete, Greece.
49. Risk Factors for Disease Progression in Patients with Lower Urinary Tract Symptoms/BPH: a Systematic
Analysis of Expert Opinion. European Association of Urology, March 25, 2004, Vienna, Austria.
50. Clinical Management of BPH: What is the right place of Serenoa repens? European Association of Urology,
Stockholm, Sweden, March 18, 2009.
51. Phytotherapy for Treatment of BPH: Fact or Fiction. National Medical Association, Las Vegas NV, July 27,
2009.
52. Treating prostate cancer in the HIV positive patient. NY AUA, Juneau, Alaska, August 24, 2009.
53. Complementary Medicine in Urology. NY AUA, Seward, Alaska, August 21, 2009.
54. The Use of Complementary Medicine in Urology: What is the Evidence? Arabian Urological, Cairo, Egypt,
October 10, 2009.
55. Genitalial Manifestations of Medical Diseases. New York Section, American Urological
Association, Krakow, Poland, October 5, 2010.
56. The Role of Anti-Androgens in the Management of Prostate Cancer. New York Section, American Urological
Association, Normandy, France, September 13, 2011.
57. Management of Male Lower Urinary Tract Symptoms: Ability to Correctly Identify and Consequences of
Incorrect Consumer Decision. International Continence Society, Montreal, Canada, October 7, 2015.
58. Microscopic Hematuria Screening in a Male Consumer Population with Lower Urinary Tract Symptoms.
International Continence Society, Montreal, Canada, October 7, 2015.
Invited Lectures:
1. Skin Cancer of the Male Genitalia. Dermatology Grand Rounds, The Johns
Hopkins Hospital, December 22, 1983.
2. Advances in the Management of Localized Prostate Cancer: Potency-Preserving
Radical Retropubic Prostatectomy. Urology Grand Rounds, Maimonades Hospital
November 22, 1985, Brooklyn, New York.
3. Current Advances in Prostate Cancer. Urology Grand Rounds, New York
Hospital, October 23, 1986, New York, New York.
4. Current Advances in Hormonal Therapy for Metastasis Prostate Cancer. Urology
Grand Rounds, New York University Hospital, February 23, 1987, New York, NY.
5. Ketoconazole in the Management of Prostate Cancer. Urology Grand Rounds,
John Hopkins Hospital, April 14, 1987, Baltimore, Maryland.
6. Urological Cancer in Men. American Cancer Society. June 1, 1988, New York,
New York.
7. Cancer of the Male Genitalia. Urology Grand Rounds, Bowman Grey Medical
Center. June 20, 1990, Winston-Salem, North Carolina.
8. State of the Art: Alpha Sympatholytic Therapy for the Treatment of BPH
New York Section of the American Urological Association, October 1-6, 1990
Budapest, Hungary.
9. Hormonal Therapy for Prostate Cancer, Suffolk County Urology Association
April 25, 1991, Smithtown, New York.
10. Current Advances in Treatment of Prostatic Hypertrophy. Departments of
Pharmacology and Molecular Biology and Medicine Grand Rounds, The
Chicago Medical School, September 4, 1991, Chicago, IL.
11. Therapy of Chronic Prostatitis. Research Seminar, Abbott Laboratories,
September 5, 1991, Chicago, IL.
12. Cancer of the Male Genitalia. Urology Grand Rounds, Lenox Hill Hospital,
September 26, 1991, New York, NY.
13. Non-Surgical Therapies for BPH. Medical Grand Rounds, St. Vincent’s Medical
Center, April 21, 1992, Bridgeport, CT.
14. Urological Manifestations of AIDS. Medical Grand Rounds. Elizabeth General
Hospital, May 20, 1992, Elizabeth, NJ.
15. Update on Prostate Cancer. Tumor Board Conference, Sacred Heart Hospital,
May 29, 1992, Allentown, PA.
16. Alternate Therapies for BPH. Medical Grand Rounds, Valley Hospital,
June 17, 1992, Ridgewood, NJ.
17. Update on the Medical Management of BPH. Urology Grand Rounds,
Wayne General Hospital, October 8, 1992, Wayne, NJ.
18. New Perspectives in the Management of Benign Prostatic Hyperplasia, Urology
Rounds, Overlook Hospital, November 4, 1992, Summit, NJ.
19. Evaluation of BPH. Primary Care Rounds, St. Mary’s Hospital, November 10, 1992,
Hoboken, NJ.
20. Current Management of BPH. Medical Grand Rounds, Passaic General Hospital,
November 18, 1992, Passaic, NJ.
21. New Approaches to the Treatment of BPH. Medical Rounds, Brunswick Hospital,
January 21, 1993, Amityville, NY.
22. New Approaches to the Treatment of BPH. Medical Rounds, St. Francis Hospital,
January 26, 1993, Jersey City, NJ.
23. Treatment BPH in 1993. Medical Grand Rounds, Bergen Pines
Hospital, January 27, 1993, Paramus, NJ.
24. Management of BPH. Medical Ground Rounds, Warren General Hospital,
March 3, 1993, Philipsberg, NJ.
25. Medical Management of BPH. Medical Grand Rounds, Holy Name Hospital,
March 9, 1993, Teaneck, NJ.
26. Screening and Detection of Prostate Cancer in the Primary Care Setting.
Connecticut State Medical Society. March 10, 1993, Hartford, CT.
27. Prostate Cancer: Epidemiology, Natural History, Diagnosis and Staging.
New York Section, American Urological Association, Post-Graduate Seminar,
March 20, 1993, New York, NY.
28. Treatment Options in the Treatment of BPH. Eastern Regional Oestopathic
Convention, April 15-18, 1993, Atlantic City, NJ.
29. A Multicenter Sudy of Terazosin in the Treatment of BPH. Urology Advisory
Council: Future Directions in Research and Clinical Practice, April 30, 1993.
Abbott Park, IL.
30. Medical Treatment Options: A Comparison of Clinical Efficacy. Urology Advisory
Council: Future Directions in Research and Clinical Practice,
April 30, 1993, Abbott Park, IL.
31. Alpha Blockade in the Management of Benign Prostatic Hyperplasia. New York
Section, American Urological Association, June 26, 1993, Montauk, NY.
32. State of the art: Continent Urinary Diversion. New York Section, American
Urological Association, October 10-16, 1993, Florence, Italy.
33. Current Status of Alpha Blockade in the Management of BPH. Urology Grand
Rounds, Hackensack Medical Center, November 18, 1993, Hackensack, NJ.
34. Medical Management of BPH. Primary Care Grand Rounds, Wyckoff Medical
Center, January 11, 1994, Brooklyn, NY
35. Alpha Blockers in the Management of BPH. Urology Grand Rounds, Long Island
Jewish Hospital, March 10, 1994, Hillside, NY.
36. Current Controversies is the Management of Prostate Cancer. Monmouth County
Urological Association, March 16, 1994, Spring Lake, NJ.
37. Alpha Blockers in BPH. Bergen-Passaic County Osteopathic Society,
April 5, 1994, Ridgewood, NJ.
38. Advances in the Hormonal Therapy of Prostate Cancer. Oncology Grand
Rounds, Beth Israel Hospital, April 6, 1994, New York, NY.
39. Medical Management of BPH, Medical Grand Rounds, Central Suffolk Hospital
April 7, 1994, Riverhead, NY.
40. Management of BPH, Medical Grand Rounds, Bergen Pines Hospital,
April 13, 1994. Paramus, NJ.
41. Genitalia Malignancies. Urology Grand Rounds, New York University Hospital,
May 11, 1994, New York, New York
42. Combined Androgen Deprivation Therapy for Prostate Cancer. Urology Rounds,
Good Samaritan Hospital, May 26, 1994, West Islip, NY.
43. Medical Management of BPH, Medical Grand Rounds, St. Charles Hospital,
June 7, 1994, Port Jefferson, New York
44. Prostate Cancer Update. Medical Grand Rounds, South Nassau Community Hospital,
June 14, 1994, Oceanside, New York
45. Gangrene of Genitalia. New York Section, American Urological Association,
June 4, 1994, Rye Brook, NY.
46. Natural History of Prostate Cancer. New York Section, American Urological Association,
June 4, 1994, Rye Brook, NY.
47. Medical Management of BPH. Urology in the 1990’s Seminary, October 22, 1994,
Orlando, FL.
48. Treatment of BPH. New York State Physician’s Assistants Annual Meeting
October 22, 1994, Saratoga Springs, NY.
49. Pharmacotherapy for BPH. Austrian Urological, November 10, 1994, Salzburg, Austria.
50. Hormonal Therapy for Prostate Cancer. Oncology Rounds, Lenox Hill Hospital
January 17, 1995, New York, NY.
51. Treatment of Metastatic Prostate Cancer. Urology Rounds, Brookdale Hospital
January 18, 1995, Brooklyn, NY.
52. Pharmacotherapy for BPH. Primary Care Grand Rounds, All Saints Hospital,
February 28, 1995, Fort Worth, Texas.
53. Pharmacotherapy for BPH. Combined Urology and Medicine Rounds, Southside
Hospital, March 3, 1995, East Islip, NY.
54. Genitourinary Manifestations of AIDS. New York Section AUA, The Greater
New York Urology Symposium, March 4-5, 1995, New York, NY.
55. Evaluation and Treatment of BPH, Primary Care Rounds, Brookhaven Hospital,
April 21, 1995, East Patchogue, NY.
56. A.H.C.P.R. Guidelines for the Treatment of BPH. Primary Care Rounds,
Charlotte Hungerford Hospital, April 26, 1995, Torrington, CT.
57. A.H.C.P.R. Guidelines for the Treatment of BPH. Medical Grand Rounds.
St. Joseph’s Hospital, April 27, 1995, Syracuse, NY.
58. Epidemiology, Natural History and Etiology of BPH, National Association
Managed Care Physicians, May 11, 1965, Palm Springs, CA.
59. The HYCAT Study. National Association Managed Care Physicians,
May 11, 1995, Palm Springs, CA.
60. Natural History of BPH. Academy of Managed Care Pharmacists, May 18, 1995
Toronto, Canada.
61. The HYCAT Study. Academy of Managed Care Pharmacists, May 15, 1995,
Toronto, Canada.
62. BPH: Pathophysiology, Diagnosis and Treatment. Medical Grand Rounds,
St. Benedictine Hospital. June 10, 1965, Kingston, NY.
63. Current Advances in the Hormonal Therapy of Prostate Cancer. Medical Rounds,
Our Lady of Mercy Hospital, June 21, 1995, Bronx, NY.
64. BPH: A.H.C.P.R. Guidelines. Primary Care Rounds, Lenox Hill Hospital,
July 21, 1995, New York, NY.
65. Prostate Disease: BPH and Cancer. Medical Staff Conference, Peninsula General
Hospital, September 14, 1995, Queens, NY.
66. BPH: A.H.C.P.R. Guidelines, Medical Grand Rounds, St. John’s Riverside
Hospital, September 26, 1995, Yonkers, NY.
67. BPH: Pathophysiology, Diagnosis and Treatment. Medical Grand Rounds,
Franklin Hospital, September 28, 1995, Valley Stream, NY.
68. BPH: Pathophysiology, Diagnosis and Treatment. Medical Grand Rounds,
VA Medical Center, October 11, 1995, NJ.
69. Intermittent Androgen Ablation for Prostate Cancer. Oncology Rounds,
Winthrop Hospital, October 14, 1995, Mineola, NY.
70. BPH: Evaluation and Management, Medical Records. VA Medical Center,
November 8, 1995, East Orange, NJ.
71. Urinary Tract Infections in HIV Positive Patients. Medical Society of Delaware.
Infectious Disease Update: 1995, November 14, 1995, Wilmington, DE.
72. BPH: Evaluation and Management Medical Rounds. Clara Mass Medical Center,
December 6, 1995, Belleville, NJ.
73. BPH: Epidemiology, Diagnosis and Management. Medical Grand Rounds, VA
Medical Center, December 21, 1995, Buffalo, NY.
74. Phytotherapy for BPH: BPH Update Symposium, February 2, 1996, San Diego, CA.
75. Economic Modeling for BPH. BPH Update Symposium, February 3, 1996, San Diego, CA
76. Symptoms of BPH, New York Section, American Urological Association 1996, Annual
Urology Symposium, March 10, 1996, New York, NY.
77. Urinary Tract Infections in AIDS. Visiting Professor Lecture, Washington, D.C.
Urological Society, March 21, 1996, Washington, DC.
78. Prostatitis. Primary Care Grand Rounds, Holy Name Hospital, April 23, 1996,
Teaneck, NJ.
79. Evaluation and Management of BPH. Medical Housestaff Rounds, St. Vincent’s
Hospital, November 13, 1996, New York, NY.
80. Phytotherapy for BPH. Seventh Nutraceutical Conference, November 20, 1996,
New York, NY.
81. New Advances in Treatment of Prostate Cancer. Tumor Board, Kuakini Medical Center,
March 20, 1997, Honolulu, HI.
82. Prostate Cancer Update. Oncology Conference, Queen’s Medical Center,
March 20, 1997, Honolulu, HI.
83. Phytotherapy for BPH. Visiting Professor Lecture, Tripler Army Medical Center,
March 25, 1997.
84. AIDS and the Urologist. Visiting Professor Lecture, Tripler Army Medical Center,
March 25, 1997.
85. Prostate Cancer Case Reviews. Visiting Professor Lectures, Tripler Army Medical
Center, March 26, 1997.
86. Currents Advances in Diagnosis and Management of Prostate Cancer. Joint
Medical Rounds, Encino-Tarzana Regional Medical Center, March 27, 1997.
Tarzana, CA.
87. Update on Prostate Cancer. Chilton Memorial Hospital, Pompton Plains, NJ,
June 27, 1997.
88. Alternative Hormonal Therapies for Prostate Cancer. Department of Urology
Jefferson Medical School Annual Urology Update, Philadelphia, PA, October 30, 1997.
89. New Medical Therapies for BPH. Urology Grand Rounds, SUNY-Syracuse,
December 18, 1997.
90. Medical Therapies for BPH. Medical Grand Rounds, Lincoln Hospital, Bronx, NY
December 19, 1997.
91. Urological Manifestation of AIDS. Urology Grand Rounds, Henry Ford Hospital,
Detroit, MI, January 31, 1998.
92. What do you want to achieve in treating BPH? Satellite Symposium, European
Association Urology, Barcelona, Spain, March 21, 1998.
93. Tamsulosin and other Medical Therapies for BPH. Northern Miami Urological
Society, Miami, Florida, April 23, 1998.
94. Phytotherapy for BPH: A Critical Appraisal. Delaware Urological Society,
Wilmington, DE, April 24, 1998.
95. Phytotherapy for BPH. Visiting Professor Lecture, Illinois Urological Society,
Delavan, WI, September 11, 1998.
96. Urological Manifestations of AIDS. Visiting Professor Lecture, Illinois Urological
Society, Delavan, WI, September 12, 1998.
97. Evaluation and Management of BPH. Medical Grand Rounds, St. Joseph’s Hospital,
Baltimore, MD, September 16, 1998.
98. Cranberry Juice and Cipro: A Virtual Case. Tenth Nutraceutical Conference, New York, NY
November 1998.
99. Treatment of BPH: Goals of Therapy. Urology Grand Rounds. Stony Brook Medical Center,
Stony Brook, NY, February 5, 1999.
100. Comparison of Alpha Blockers, AUA Post-Graduate Course, Dallas, TX,
May 4, 1999.
101. The Role of Anti-Androgen Therapy in The Treatment of Prostate Cancer. Prostate
Cancer Update. Beth Israel Hospital, New York, NY, June 18, 1999.
102. Complementary Medications in the Treatment of BPH. Urology Grand Rounds. Beth
Israel Hospital, New York, NY, September 2, 1999.
103. Alternative Medications for BPH. AUA Post-Graduate Course, Atlanta, GA,
May 3, 2000.
104. Goals of Therapy for BPH. Fifth International Consultation on BPH, Paris, France,
June 26, 2000.
105. Complementary Medications for BPH. Visiting Professor Lecture, Arizona Urological
Society, Tucson, AZ, October 14, 2000.
106. Genitalia Manifestations of Medical Diseases. Visiting Professor Lecture, Arizona
Urological Society, Tucson, AZ, October 14, 2000.
107. Complementary Medications for BPH. Western Section, American Urological
Associate, Palm Springs, CA, November 6, 2000.
108. Genitalia Diseases. Urology Grand Rounds. Mt. Sinai Hospital, New York, NY
May 16, 2001.
109. Goals of Therapy in BPH. Satellite Symposium, American Urological Associate,
Anaheim, CA June 1, 2001.
110. Complementary Medications for BPH. AUA Post-Graduate Course, Anaheim, CA,
June 3, 2001.
111. Genital Diseases. Urology Grand Rounds. New York Medical College, Valhalla, NY,
August 16, 2001.
112. Medical Therapy for BPH. Visiting Professor Lecture, Urology Grand Rounds, Valhalla, NY
August 16, 2001.
113. Complementary and Alternative Medicine Usage in Urology. CAP CURE Symposium on
PC-SPES, Los Angeles, CA, October 15, 2001.
114. Alternative Therapy for Prostate Cancer. Urology Grand Rounds, University of Chicago,
Chicago, IL, October 31, 2001.
115. Alternative Therapy for Prostate Cancer. Urology Grand Rounds, John Hopkins Hospital
Baltimore, MD, November 8, 2001..
116. Phytotherapy for BPH. Urology Grand Rounds, New York Cornell Hospital, New York, NY,
December 13, 1001.
117. New Medical/Herbal Approaches in the Treatment of BPH. AUA 100th Anniversary
Celebration Meeting, New York, NY, February 16, 2002.
118. Complementary Medications for BPH. AUA Post-Graduate Course, Orlando, FL
June 2, 2002.
119. Androgen Supplementation and Prostate Safety. Third International Consultation on
Prostate Cancer, Paris, France, June 23, 2002.
120. Urological Manifestations of HIV Disease. Visiting Professor Lecture, Puerto Rican
Urological, San Juan, PR, November 14, 2002.
121. Alternative Hormonal Therapy for the Treatment of Prostate Cancer. Visiting Professor
Lecture, Puerto Rican Urological, San Juan, PR, November 14, 2002.
122. Long-term Medical Management of BPH. Visiting Professor Lecture, Puerto Rican
Urological, San Juan, PR, November 16, 2002.
123. Alternative Therapies in Urology, Visiting Professor Lecture, Puerto Rican Urological,
San Juan, P.R., November 16, 2002.
124. Complementary Medications for BPH. AUA Post-Graduate Course, Chicago, IL,
April 29, 2003.
125. MTOPS: It’s Impact Upon BPH Management. Long Island Jewish Hospital Men’s
Health Symposium, New Hyde Park, New York, NY, May 31, 2003.
126. Prevention of Prostate Cancer: Diet, Drugs and Supplements. Long Island Jewish
Hospital Men’s Health Symposium, New Hyde Park, NY, June 1, 2003.
127. Alternative Therapies in the Prevention and Treatment of Prostate Cancer. 51st Kimbrough
Urological Seminar, San Antonio, Texas, January 14, 2004.
128. Patient Risk Profiles for LUTS/BPH Progression. European Association of Urology, Austria, Vienna,
March 24, 2004.
129. Complementary Medications for BPH: Fact or Fiction? AUA Post-Graduate Course, San Francisco, CA,
May 9, 2004.
130. BPH Management in 2004. Medical College of Virginia Urology Grand Rounds, Richmond, VA, August 6, 2004.
131. BPH/LUTS and Sexual Dysfunction: Implications in Treatment and Management. Satellite Symposium, Societie of International Urology, Honolulu, HA, October 4, 2004.
132. Medical Therapy for BPH: Are All Drugs Equal? University of Wisconsin LUTS Symposium, Madison, WI, October 16, 2004
133. Herbal Preparations for BPH: Mechanism of Action. University of Wisconsin LUTS Symposium, Madison, WI, October 16, 2004.
134. Genitalial Diseases. Lent Visiting Professor Lecture, SUNY Buffalo, Buffalo, NY, May 5, 2005.
135. Pathophysiology and Management of BPH. Lent Visiting Professor Lecture, SUNY Buffalo, Buffalo, NY,
May 6, 2005.
136. Alternative Medications for BPH. AUA Post-graduate course. San Antonio, Texas, May 24, 2005
137. CAM in Urology. Basic Science Research Seminar, AUA Annual meeting, San Antonio, Texas,
May 22, 2005.
138. Phytotherapy for BPH: Fact or Fiction. Marie Jong Visiting Lecturer, Ohio State Urological meeting,
Cincinnati, Ohio, March 18, 2006.
139. Evidence based complementary and alternative medicine in Urology: State-of- the Art. American Urological
Association, Atlanta, GA, May 22, 2006.
140. Alternative Medications for BPH. AUA Post-graduate course. Atlanta, GA, May 22, 2006.
141. CAM in Urology. Piedmont Urological Association, Camden, NJ, June 27, 2006.
142. The Management of Prostate Cancer in HIV Positive Patients. Visiting Professor, Mexican Urological Society.
Puerta Vallarta, Mexico, November 17, 2006.
143. Complementary and Alternative Medicine in Urology. Visiting Professor, Mexican Urological Society,
Puerta Vallarta, Mexico, November 18, 2006.
144. Complementary Medicine in Urology. AUA Post-graduate Course. Anaheim, CA, May 16, 2007.
145. Diseases of the Genitalia. Johns Hopkins Urology Rounds, Baltimore, MD, August 28, 2008.
146. Diseases of the Genitalia. Urology Grand Rounds, Lennox Hill Hospital, New York, NY, March 25, 2010.
146. Genitalial Manifestations of Medical Diseases. Urology Grand Rounds, Montefiore Hospital, March 12, 2011.
147. Highlights of AUA: Infection/Imflammation. Plennary Session, AUA Annual Meeting, Atlanta, Georgia,
May 22, 2012.
148. What I Tell My Patients About Vitamins and Supplements. Urology Grand Rounds, Montefiore Hospital,
June 7, 2014.
149. Vitamins and Supplements In Urology, Urology Grand Rounds, Mount Sinai, October 6, 2014.
.
-----------------------
4
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- 0.05 significance level
- 0.05 significance level calculator
- public administration circular 03 2016
- 0 05 significance level calculator
- 03 2016 circular
- 2.05 apy
- interpreting 0.05 significance level
- 0 05 significance level
- interpreting 0 05 significance level
- p value 0 05 means
- p 0 05 is significant
- is 0 05 significant